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Gut Reaction 
Environmental Effects 
  Human Microbiota
on 
the
1)  Ruminococcus
2)  Bifidobacterium
3)  Peptostreptococcus
4)  Staphylococcus
5)  Lactobacillus
6)  Acidaminococcus
7)  Fusobacterium
8)  Eubacterium
9)  Clostridium 
10) Coprococcus
11) Escherichia
12) Butyrivibrio
13) Bacteroides 
14) Brachyspira
L
iving with each of us—on 
our skin, in our mucosa, and 
in our gastrointestinal (GI) 
tract—are microorganisms 
whose numbers dwarf the number of our 
own cells and genes. Although some of 
these microbes are pathogens, most are 
harmless or even beneficial. The body’s 
assortment of microorganisms, collec-
tively called the microbiota, is similar to 
an organ in that it performs functions 
essential for our survival. Some microbes 
produce vitamins and other essential 
nutrients. Many metabolize food that 
we can’t digest on our own. They also 
break down drugs and toxins, and regu-
late many aspects of innate and acquired 
immunity,  protecting  the  host  from 
infections and chronic inflammation, 
as well as possibly many immune-based 
disorders. And just as with the heart or 
the lungs, when an environmental agent 
alters the function of the microbiota, the 
result can be disease. 
Most  environment–microbiota 
research has focused on the gut, home 
to some 100 trillion microorganisms—
the vast majority of our complement of 
microbes. Shifts in the microbial species 
that reside in our intestines have been 
associated with a long list of pathologies, 
from allergies and autoimmune diseases 
to obesity and cancer. Some researchers 
even suspect that the microbiota may 
play a role in autism spectrum disorders 
(ASDs). 
Each of us carries thousands of bac-
terial species in our gut along with a 
few species of other types of organisms. 
Although all humans have grossly similar 
microbiota, no two people have exactly 
the same composition of bacterial species 
in their guts—in fact, each individual’s 
microbial consortium may turn out to 
be as unique as a fingerprint. Yet a study 
published 22 January 2009 in Nature 
reported that, although individual bac-
terial species can differ widely between 
people, the species tend to encode the 
same metabolic pathways, says coauthor 
Ruth Ley, an assistant professor of micro-
biology at Cornell University. “You see 
the same gene functions regardless of the 
suite of bacteria present,” Ley says.
(opposite) The gut contains thousands of microbial species, including:   
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Outside influences such as antibiotic use, 
diet, and psychological stress have shown 
strong correlations with what lives inside our 
bodies, and researchers are just beginning 
to understand how these environmental fac-
tors may affect our health. Recent advances 
in genomic sequencing technologies have 
pushed the field forward. Whereas scientists 
once could study only those micro  organisms 
that are easily cultured in a lab—which pre-
cludes most of the anaerobic gut microbes—
they can now sequence the entire collection 
of DNA in a microbial sample and identify 
the component species. This approach, called 
metagenomics, has been key to many recent 
advances in understanding the relationship 
between our microbiota and our health. 
Our Microbial Partners 
The infant GI tract is colonized with micro-
organisms in a complex process that begins 
during birth and is thought to depend partly 
on host genetics and partly on the microbes 
that happen to be in the child’s environ-
ment. Babies delivered via cesarean section 
show different microbial profiles than those 
born vaginally—whereas vaginally delivered 
infants are colonized at first by fecal and vag-
inal bacteria from the mother, infants born 
through cesarean section are exposed initially 
to bacteria originating from the hospital envi-
ronment and health care workers. Research 
by Giacomo Biasucci et al. in the September 
2008 issue of the Journal of Nutrition showed 
that the gut microbiota after cesarean deliv-
ery was characterized by an absence of 
Bifido  bacteria species, which are thought to 
be important to the postnatal development 
of the immune system, whereas vaginally 
delivered neonates showed a predominance 
of these species. In general, cesarean-born 
children also tend to have delayed access to 
mother’s milk, which has a potent influence 
on gut microbiota. [For more information, 
see “Contaminants in Human Milk: Weigh-
ing the Risks against the Benefits of Breast-
feeding,” EHP 116:A426–A434 (2008).]
Throughout the first year of life, the 
makeup of babies’ gut microbiota can vary 
widely and is still based largely on the strains 
of bacteria in their mothers’ bodies as well 
as those in the immediate environment. 
Research published by Chana Palmer et al. 
in the 26 June 2007 edition of PLoS Biology 
showed that, at 1 year of age, infants started 
to converge toward a microbiota profile that 
looked more like the adult GI tract, particu-
larly as they began to eat solid foods. Once 
fully developed in adulthood, the intestinal 
microbiota is thought to remain quite stable 
over months or years. 
Much of what we know about the influ-
ence of microbes on our biology has come 
from studying “germ-free” rodents, which 
are born and raised in sterile environments. 
Because these animals have no micro  biota, 
researchers can deduce which aspects of 
mammalian biology and physiology nor-
mally rely on these symbionts. They can 
also then inoculate the germ-free animals 
with various bacteria to see how colonization 
affects them (the resulting animal is referred 
to as “gnotobiotic”). Such studies have shown 
that the gut microbiota is essential for nor-
mal development and function of both the 
GI tract and the immune system. 
“Work over the past decade or two links 
intestinal microbiota very closely with many 
parameters of host biology in both health 
and disease,” says Justin Sonnenburg, an 
assistant professor of microbiology and 
immunology at Stanford University. In most 
cases, however, the microbiota–disease con-
nection remains simply a correlation; it’s not 
yet clear if microbial shifts actually cause 
disease or if they are simply a reflection of 
a diseased state.  Moreover, exactly how or 
why our balance of microorganisms some-
times shifts in an unhealthful direction—a 
condition known as dysbiosis—is frequently 
unclear.
According to a report by Mohamed Oth-
man and colleagues in the January 2008 
issue of Current Opinion in Gastroenterology, 
many problems related to dysbiosis actually 
may be manifestations of a condition called 
small intestinal bacterial overgrowth (SIBO). 
Most gut microbes are supposed to be in the 
colon, with relatively few in the small intes-
tine. Over time, with changes in intestinal 
anatomy, motility, and gastric acid secretion, 
microbes may migrate from the colon up into 
the small intestine, resulting in SIBO. SIBO 
is most common in older people, although 
prevalence reports vary widely. Symptoms of 
SIBO include diarrhea, abdominal pain, and 
weight loss resulting largely from malabsorp-
tion of micronutrients.  
The Hygiene Hypothesis 
Over the past few decades, the increas-
ing  incidence  of  several  atopic  and 
autoimmune diseases in developed coun-
tries  has  led  to  the  so-called  hygiene 
 
 
T
he microbiota is similar to an organ in that it 
performs functions essential for our survival. 
And just as with the heart or the lungs, when an 
environmental agent alters the function of the 
microbiota, the result can be disease. 
Bacteroides species are some of the most common bacteria in 
the human gut. They are involved in many important metabolic 
activities, including fermentation of carbohydrates, utilization 
of nitrogenous substances, and biotransformation of bile acids 
and other steroids. But Bacteroides can also cause many types 
of infections and abscesses in the GI tract and elsewhere in 
the body. 
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Temporal Profiles of the Most Abundant Gut Microbes as Measured in 14 Infants
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Despite wide variation in microbial makeup, the microbiota of a group of 14 infants began to converge in a common profile 
toward the end of the first year of life. In the group depicted above, infants 1, 2, 11, 13, and 14 were delivered by cesarean 
section. Infants 1, 4, 6, 8, 10, and 12 received antibiotics before 6 months of age. Infants 3, 5, 6, 10, 11, 13, and 14 were fed 
infant formula at least part of the time. Infants 13 and 14 were fraternal twins. 
Source: Palmer C, et al. 2007. Development of the human infant intestinal microbiota. PLoS Biol 5(7):e177; doi:10.1371/journal.pbio.0050177           
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hypothesis. The idea is that develop-
ing infants need exposure to plenty of 
microorganisms—both pathogenic and 
commensal—in order for their immune 
systems to develop and function properly. 
According to the hygiene hypothesis, in 
countries that have very high levels of 
hygiene (as reflected by the use of refrig-
eration, pasteurization, water treatment, 
and food processing to discourage bacte-
rial growth), children aren’t exposed to 
enough of these microbes. “We’re walking 
around with a partially ablated micro-
biota, essentially,” Sonnenburg says. 
Several studies have reported a strong 
correlation between disrupted micro  bial 
composition and allergies and asthma. 
Infants with atopic eczema had lower 
microbial diversity in their guts as well as 
fewer species of Bifidobacteria, compared 
with healthy infants, according to a study 
by Mei Wang et al. in the January 2008 
Journal of Allergy and Clinical Immunology. 
A prospective study by Stijn L. Verhulst 
and colleagues, published in the Novem-
ber 2008 Journal of Asthma, found that 
increased concentrations of anaerobic bacte-
ria in the feces of 3-week-old infants corre-
lated with increased probability of wheezing 
in the first year of life—a symptom that 
can be associated with asthma or other lung 
problems later in life—although Clostridi-
um bacteria seemed to be protective.
Dysbiosis has also been seen in inflam-
matory bowel disease (IBD), a group of 
intestinal disorders that includes ulcer-
ative  colitis  and  Crohn  disease.  Some 
microbial strains—notably of the Bacte-
roides and Clostridia species—can produce 
entero  toxins or possess protein-degrading 
properties that enhance mucosal perme-
ability and bacterial uptake. In the January 
2004 issue of Gut, Cyrus Tamboli and col-
leagues wrote that these strains can colonize 
the intestinal mucosa and cross the epitheli-
al barrier, whereupon they interact with res-
ident macrophages and trigger the synthesis 
of pro  inflammatory cytokines by infected 
epithelial cells and macrophages. In other 
cases, IBD patients seem to have an abnor-
mal proinflammatory immune response to 
normal commensal bacteria, as reported by 
H. Matsuda et al. in the January 2000 Jour-
nal of Gastroenterology and Hepatology.  
Pervasive antibiotic use may also be dis-
rupting the microbiota among people liv-
ing in developed countries. Both human 
and animal studies have shown that even 
a one-time antibiotic treatment can lead to 
decreases in bacteria usually considered bene-
ficial, such as Bifidobacteria and Lacto  bacilli, 
as well as increases in potential pathogens 
such as Clostridium difficile and the yeast 
Candida albicans. In the short term, such 
shifts in microbiota can cause yeast infec-
tions and GI symptoms including bloating, 
abdominal pain, and diarrhea, but recent 
work suggests the consequences may be 
much longer-lasting and more serious. 
A study by Les Dethlefsen et al., pub-
lished 18 November 2008 in PLoS Biology, 
reported that most types of intestinal bac-
teria returned to their pretreatment levels 
by 4 weeks after the end of a 5-day course 
of ciprofloxacin, a widely used broad-
spectrum antibiotic. But a few types of bac-
teria failed to recover even 6 months later. A 
study in the May 2007 issue of The ISME 
[International Society for Microbial Ecol-
ogy] Journal found that levels of some types 
of gut bacteria remained disrupted up to 
2 years after a 7-day course of clindamycin, 
the drug of choice when treating Bacteroides 
infections. 
It’s possible these long-term shifts don’t 
have any real health consequences, says 
Janet Jansson, a senior staff scientist in the 
Earth Science Division at Lawrence Berke-
ley National Laboratory and senior author 
of the ISME Journal study. “Maybe you lose 
some species or strains but get new species 
or strains that take over their functions,” she 
says. “We don’t know if it matters or not.” 
However, Jansson’s study also revealed 
a “dramatic and persistent” increase in 
levels of specific resistance genes in 
Bacteroides after clindamycin use. In the 
people they examined, resistance genes 
started out at a negligible level but “went 
up exponentially and stayed at that level 
for two years,” Jansson says. “Those genes 
really persist.” [For more information on 
antibiotic resistance genes, look for next 
month’s Focus article.]
Perhaps the classic example of how 
hygiene has altered the microbiota is that of 
Helicobacter pylori. In the 1980s, research-
ers first isolated the microbe then known 
as Campylobacter pylori, although it is now 
believed this microbe has been present in 
most human guts for millennia. Today, how-
ever, increased sanitation, hygiene, and anti-
biotic use have decimated gut populations of 
this once-ubiquitous microbe. “In developed 
countries,” wrote Martin J. Blaser in the 
October 2006 issue of EMBO [European 
Molecular Biology Organization] Reports, 
“new generations are growing up without 
our ancient companion, H. pylori, to orches-
trate their gastric hormones.” 
B
oth human and animal studies have shown 
that even a one-time antibiotic treatment can 
lead to long-term shifts in microbial populations. 
The health consequences of these long-term shifts 
are still largely unknown.
Clostridium difficile is often acquired in a hospital setting 
by patients on antibiotics. Antibiotics alter the normal flora 
of the intestines, which allows for colonization by C. difficile. 
Once colonized, the bacteria release endotoxins that can 
cause colitis and severe diarrhea.
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Although H. pylori has been shown to 
contribute to gastric adenocarcinoma and 
lymphoma, as well as ulcers, recent research 
has revealed another side of this microbe: 
In the 3 March 2004 issue of the Journal 
of the National Cancer Institue, Weimin Ye 
and colleagues confirmed that H. pylori was 
associated with a significantly reduced risk 
of adenocarcinoma in the lower esophagus. 
H. pylori is now also thought to modulate 
immunologic, endocrine, and physiologic 
functions in the stomach. In the January 
2007 issue of Seminars in Radiation Oncol-
ogy, Rebecca S. Holmes and Thomas L. 
Vaughan wrote, “The incidence of [H. pylori] 
infection has been declining in the United 
States and other developed countries, which 
may contribute to the increasing incidence of 
[esophageal adenocarcinoma].”
Because factors besides sanitary con-
ditions can confound epidemiologic stud-
ies, researchers have also turned to animal 
models to look for connections between 
the microbiota and various diseases. In 
the case of autoimmune disorders, Li Wen 
et al. reported in the 23 October 2008 issue 
of Nature that depriving mice of a microbiota 
led to faster onset and more serious disease in 
a mouse model of type I diabetes. An earlier 
report by S. Brugman et al. in the September 
2006 issue of Diabetologia used a rat model 
for type I diabetes. The authors observed that 
rats that eventually developed the disease had 
a lower amount of Bacteroides bacteria than 
rats that did not develop disease. Moreover, 
antibiotic treatment decreased the incidence 
and delayed the onset of diabetes, whereas 
a combination of antibiotic treatment and a 
special protective diet prevented disease alto-
gether in this diabetes-prone rat. 
Diet and Obesity 
Many of the microbial species in the gut 
metabolize food and extract calories, and 
some microbes are more efficient at this than 
others. Because individuals possess slightly 
different bacterial consortia, it is likely that 
some people’s microbes harvest more calo-
ries, perhaps making this group more likely 
to become overweight. 
In the 2 August 2005 Proceedings of the 
National Academy of Sciences, Ley and other 
researchers led by Jeffrey Gordon, director 
of the Center for Genome Sciences at 
Washington University, found that the gut 
microbiota of genetically obese mice con-
tained a high percentage of bacteria from 
the phylum Firmicutes whereas their lean 
littermates had more bacteria from the phy-
lum Bacteriodetes. In the 21/28 December 
2006 issue of Nature, Ley reported the same 
observation in obese and lean human vol-
unteers. She also found that the micro  biota 
of obese people who lost weight through a 
low-calorie diet shifted to look more like 
that of leaner people. 
It’s difficult to say which came first in 
some of these studies—obesity or the altered 
microbiota. In another study from the same 
Washington University laboratory, also pub-
lished in the 21/28 December 2006 issue of 
Nature, germ-free mice were colonized with 
the microbiota of either obese mice or lean 
mice. Mice that received the obese micro-
biota gained a higher percentage of body 
fat than mice receiving the lean microbiota 
(47.0% versus 0.86%), suggesting that micro-
biota shifts may contribute to obesity onset. 
The researchers also found that the obese 
microbiota, which contained more genes 
involved in breaking down sugars, appeared 
to actually harvest more energy from the 
same diet than did the lean microbiota. The 
transplant experiments provided functional 
evidence that this difference may be biologi-
cally relevant. 
Along with the observation that differ-
ent microbes and microbial combinations 
may influence body weight differently, other 
effects are being defined with respect to 
changes in human metabolism. For example, 
dysbiosis has been identified as inflam  matory 
factors that promote insulin resistance and 
weight gain, as Yolanda Sanz et al. pointed 
out in a review published online 3 Decem-
ber 2008 ahead of print in Interdisciplinary 
Perspec  tives on Infectious Diseases. 
Even when not related to obesity, dietary 
differences appear to influence our micro-
biota, although exactly how is still somewhat 
of a mystery, says Nita Salzman, an assistant 
professor of pediatrics at the Medical College 
of Wisconsin. Breastfed infants tend to have 
more Bifidobacteria and Lactobacilli in their 
guts than do formula-fed infants. In a study 
reported by Johan Dicksved et al. in the April 
2007 issue of Applied and Environmental 
Microbiology, children raised according to the 
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W
ork over the past decade or two links intestinal 
microbiota very closely with many parameters 
of host biology in both health and disease. In most cases, 
however, the microbiota–disease connection remains 
simply a correlation; it’s not yet clear if microbial 
shifts actually cause disease or if they simply reflect 
a diseased state.  
Helicobacter pylori is the main cause of chronic superficial gastritis 
and is associated with both gastric and duodenal ulcers, yet it is 
also associated with a reduced risk of adenocarcinoma in the lower 
esophagus. It lives in the interface between the surface of gastric 
epithelial cells. 
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“anthroposophic” lifestyle touted by philoso-
pher Rudolf Steiner—with restricted anti-
biotics and plenty of microbe-rich fermented 
foods—showed higher microbial diversity 
than farm children, whose diets included 
more farm-produced animal products. 
“The diet definitely can impact the 
[microbial] composition,” Ley says. It’s also 
likely that preservatives and other chemicals 
in our food, as well as the antibiotics and 
chemicals that we feed our livestock, influ-
ence our microbiota, says Salzman. “All of 
these things probably have an impact on our 
colonization,” she says. But what exactly such 
changes mean for health is still obscure.
The Brain–Gut Connection
Some research suggests the microbiota may 
also be implicated in neurologic conditions. 
“There are multiple interfaces where the 
microbiota could impact our nervous sys-
tem,” Sonnenburg says. Enteric neurons 
innervate the gut and transmit signals from 
it to the nervous system. The microbiota 
also produces metabolites that are absorbed 
into the bloodstream, and some of these 
metabolites can cross the blood–brain bar-
rier. But other studies have failed to find 
evidence of any connection between the 
microbiota and neurologic problems, and 
details of potential mechanisms are still 
scarce. “There is a good theoretical basis 
for the microbiota having an impact on our 
nervous system and, potentially, on cogni-
tion,” Sonnenburg says. “But we’re at the 
very early stages of [study].” 
Psychological stress appears to reduce the 
numbers of Lactobacilli species in the human 
gut while increasing the growth of pathogens 
such as Escherichia coli and Pseudomonas spe-
cies, as reported by Femke Lutgendorff et al. 
in the June 2008 issue of Current Molecu-
lar Medicine. In animal work published by 
Siobh  ain M. O’Mahoney and colleagues in 
the February 2009 issue of Biological Psychia-
try, rat pups were stressed by separating them 
from their mothers for 3 hours daily between 
postnatal days 2–12 (the pups still received 
mother’s milk). Compared with controls, 
the stressed pups showed markedly altered 
fecal microbiota. Similar findings have been 
reported in infant rhesus monkeys separated 
from their mothers and in adult rats exposed 
to chronic psychological stress. 
The disease ramifications of stress-
induced changes are not yet clear, but the 
scientific literature contains some intriguing 
possibilities. Psychological stress has been 
reported to exacerbate both IBD and another 
intestinal disorder, irritable bowel syndrome 
(IBS), which is characterized by a variety of 
intestinal symptoms such as abdominal pain, 
bloating, and constipation. Multiple stud-
ies—including work by Anna Kassinen et al. 
in the July 2007 issue of Gastroenterology and 
by Mazen Issa et al. in the October 2008 
issue of Inflammatory Bowel Diseases—have 
also identified an abnormal gut microbiota 
in people with these disorders. Still, as Sunny 
Singh and colleagues pointed out in a review 
published 31 March 2009 ahead of print 
in the American Journal of Gastroenterology, 
studies of the stress/bowel disorder link are 
limited by the subjective nature of docu-
menting psychological stress.
Other research has suggested that ASDs 
may be related to an altered microbiota. 
Helena Parracho and colleagues reported 
in the October 2005 Journal of Medical 
Microbiology that 91.4% of 58 autistic chil-
dren studied had a GI disorder, compared 
with 25% of otherwise-healthy siblings of 
children with ASDs and none of a group 
of unrelated healthy children. The fecal 
biota of children with ASDs consistently 
contained different Clostridium species than 
that of healthy children, as well as a sta-
tistically significant increase in clostridial 
species overall. The siblings of the children 
with ASDs exhibited intermediate levels 
of Clostridium species, suggesting that 
environmental factors and genetics may 
affect gut populations of these species. The 
researchers point out that Clostridium spe-
cies produce not only enterotoxins that lead 
to GI problems but also neuro  toxins, which 
they hypothesize could lead to characteristic 
signs of ASDs. 
In another potential gut–ASD connec-
tion, antibiotic use in rats has been shown 
to alter the animals’ gut microbiota to 
the point of almost completely inhibiting 
mercury excretion. Because mercury toxic-
ity is a leading suspect behind ASDs, some 
researchers hypothesize that high use of 
antibiotics likewise may inhibit children’s 
ability to excrete the metal, increasing the 
risk of these disorders. “Specifically,” wrote 
James B. Adams and colleagues in volume 
70, issue 12 (2007) of the Journal of Toxicol-
ogy and Environmental Health, Part A, “oral 
antibiotics will reduce the amount of nor-
mal gut flora (which demethylate methyl-
mercury) and may increase the amount of 
yeast and E. coli (which methylate inorganic 
T
he differences between each person’s microbiota 
will influence not only their health risks but 
also how they respond to medical and lifestyle 
interventions. Being able to sequence thousands of 
microbes quickly and easily will likely open the door 
to considering the individual’s microbiota in the 
development of personalized medicine.
Lactobacillus acidophilus occurs naturally in the gut, mouth, and 
vagina. It is also the most commonly used probiotic. This bacterium 
produces lactase, and L. acidophilus supplements are often given 
to lactose-intolerant individuals.
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mercury), resulting in both higher absorp-
tion and decreased excretion of mercury.” 
Finding Treatments 
As connections between the microbiota and 
disease are revealed, many researchers are 
hopeful that it will be possible to find novel 
treatments for these conditions by targeting 
our bacteria. There are burgeoning attempts 
to treat microbiota-associated illness with 
probiotics and prebiotics. Probiotic foods 
and dietary supplements introduce live 
microorganisms that take up residence in the 
intestines and are thought to be beneficial for 
health. They usually contain Lactobacilli or 
Bifidobacteria species, although some include 
nonpathogenic strains of Streptococci, E. coli, 
and nematode parasites. Prebiotics are made 
with ingredients such as inulin, oligosaccha-
rides, lactulose, and resistant starch, which 
are generally thought to encourage Lacto-
bacilli and Bifidobacteria growth, although 
they may stimulate other bacterial species 
as well, including less desirable Clostridium 
species, as noted by Yanbo Wang in a review 
published in the January 2009 issue of Food 
Research International. 
Among the best-supported evidence 
for probiotics is for their amelioration of 
childhood viral diarrheas, Sonnenburg 
says. “That’s pretty solid and I think widely 
accepted,” he says. Research is also convinc-
ing that, following antibiotic treatment, pro-
biotics can help the microbiota rapidly return 
to a normal composition along with reducing 
diarrhea-like bowel movements, as demon-
strated by Catherina J.M. Koning et al. in 
the January 2008 American Journal of Gas-
troenterology. 
Many studies have provided evidence 
for probiotic efficacy in conditions such as 
allergy development, ulcerative colitis, and 
Crohn disease. In mice, Lactobacilli have 
shown antidiabetic and antitumor effects. 
In their Interdisciplinary Perspectives on Infec-
tious Diseases review, Sanz and colleagues 
described preliminary evidence that pro-
biotics and prebiotics with antiinflammatory 
properties could be effective against obesity, 
diabetes, and associated disorders. For exam-
ple, the administration of a probiotic exerted 
a preventive effect against type 1 diabetes in 
a nonobese diabetic mice model via immune-
modulating mechanisms, as reported in the 
August 2005 issue of Diabetologia. 
But research findings regarding probiotic 
efficacy are not always consistent, Sonnen-
burg says. “There are some great suggestive 
studies where we see an impact of probiotics, 
but there are just as many or more where 
there’s no impact,” he says. 
A review by Darren M. Brenner and col-
leagues in the April 2009 American Journal of 
Gastroenterology determined that a particular 
strain of Bifidobacterium infantis was the only 
probiotic studied in 16 randomized controlled 
trials that consistently showed evidence of 
improving symptoms of IBS. However, the 
authors wrote, most of the trials either didn’t 
use an appropriate study design or didn’t 
sufficiently report adverse events, so it was 
impossible to assess the efficacy of other pro-
biotics. Brenner and colleagues wrote that 
future probiotic studies should use standard-
ized diagnostic criteria to allow appropriate 
assessment of probiotic efficacy. “We’re very 
much in the infancy of this field,” says Ley. 
“There’s so much we don’t understand.” 
Still, treating disease with probiotics or 
prebiotics is one of the most promising fron-
tiers in microbiota research, says Mélanie 
Gareau, a postdoctoral fellow training at The 
Hospital for Sick Children in Toronto. Her 
work, published in the November 2007 issue 
of Gut, has shown that treating stress-induced 
gut abnormalities with Lactobacilli probiotics 
not only reestablished normal gut function 
and bacterial behavior but also reduced stress 
hormone levels. “The role of probiotics in 
maintaining the colonic microbiota is defi-
nitely an interesting aspect of this exciting 
and rapidly advancing field,” she says. 
Exploring the Metagenome 
Other promising aspects of microbiota 
research include advances in sequencing 
technologies that allow huge numbers of 
humans and their microbes to be studied, 
Ley says. Global surveys of human micro-
biota, for example, may start to address issues 
of how geography, history, diet, and culture 
all feed into determining microbiota struc-
ture and function. Genomewide association 
studies are also coming down the pipeline to 
examine how genetic variation in the human 
genome predicts microbiota composition. To 
study these issues reliably, Ley says research-
ers need to profile the microbiotas of vast 
numbers of people. 
To provide a foundation to answer some 
of these questions, the National Institutes of 
Health launched the Human Microbiome 
Project at the end of 2007. The project will 
distribute an estimated $115 million over five 
years to determine what parts of the micro-
biota are similar in all humans and what 
parts differ—and how those differences may 
relate to disease. The European Commis-
sion is funding a related effort, called Meta-
genomics of the Human Intestinal Tract, 
and in October 2008 scientists from around 
the globe formed the International Human 
Microbiome Consortium to share data on 
the human meta  genome—comprising the 
genomes of all our commensal microorgan-
isms—among researchers around the world. 
Being able to sequence thousands of 
microbes quickly and easily will likely open 
up another field, according to Sonnenburg: 
the consideration of the individual’s micro-
biota in the development of personalized 
medicine. The differences between each per-
son’s microbiota will influence not only their 
health risks but also how they respond to 
interventions including probiotic treatment 
and dietary changes, he says. “We should 
think about differences in our microbiota 
being analogous to genetic differences that 
make our responses distinct,” he says. 
Simply knowing the constituents of our 
microbiota won’t be enough to reach this 
goal, according to Salzman. Even when we 
can determine the entire microbiota to the 
species level and every gene of the meta-
genome, “it’s still hard to say which of those 
things is actually important in driving health 
or disease,” she says. Efforts to provide such 
an understanding therefore are now focusing 
not on the genome sequences of resident bac-
teria but on the proteins they produce. 
In the February 2009 issue of The ISME 
Journal, Jansson’s group released an analysis 
of the human bacterial proteome—the thou-
sands of bacterial proteins that are expressed 
in our bodies. “The proteome . . . [tells] you 
what’s actually going on in the gut,” she says. 
She and her colleagues found that proteins 
involved in carbohydrate metabolism and 
food utilization were very highly expressed, 
whereas other proteins, such as those involved 
in motility, were nearly absent. They’re now 
working on analyzing the microbial pro-
teomes in people with Crohn disease. 
Another way of analyzing relevant micro-
bial function is to examine the metabolites 
produced by the microbes, which reveals 
not just what the bacteria are expressing but 
what the body is actually absorbing, Salzman 
says. A study by William R. Wikoff et al., 
published in the 10 March 2009 Proceedings 
of the National Academy of Sciences, shows 
that many aspects of mammalian metabo-
lism rely on the microbiota. In the absence 
of a microbiota, the metabolites found in the 
blood of mice were significantly changed, 
suggesting that an animal’s ability to metab-
olize drugs—and by extension, many other 
chemicals—likely relies in part on its com-
munity of microbes.  
Combining genomic inventories of the 
microbial species that live inside us with 
functional analyses of the proteins they 
express and the metabolites we absorb will 
“advance this field significantly in terms of 
understanding what’s going on and how it 
relates to disease,” Salzman says. “Techno-
logical advances have profoundly pushed the 
field, but I still think that we’re probably at 
the very beginnings.” 
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